Kyphosis

CLOUD 10 STUDIOS ANNOUNCES THE LAUNCH OF CLOUD 10 ORIGINALS

Retrieved on: 
Wednesday, August 30, 2023
Cloud, DreamWorks, The Matrix Reloaded, The Little Mermaid, Industrial Light & Magic, Kyphosis, Beauty, Workflow, Unreal Engine, Watchmen, How to Train Your Dragon, Superman/Batman, Walt Disney Imagineering, Beauty and the Beast, LAS, Fortnite, HBO Max, AAA, Magic, Warner Bros., Epic, Netflix, Hulu, Video game

DALLAS and LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- Cloud 10 Studios, led by feature-production veteran Tracey Dispensa, announces the launch of Cloud 10 Originals.

Key Points: 
  • DALLAS and LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- Cloud 10 Studios, led by feature-production veteran Tracey Dispensa, announces the launch of Cloud 10 Originals.
  • "We are very excited to be at the point where we can self-fund the development of several Cloud 10 originals working with these industry legends.
  • Cloud 10 Studios plans to execute its content as high-quality 3D animation, using both a 3D animation pipeline and a real-time pipeline leveraging Fortnite creator's Epic!
  • "We've already been using Unreal Engine for 80% of our projects at Cloud 10 Studios.

DISC Sports & Spine Center Opens New Clinic in Encino

Retrieved on: 
Thursday, May 25, 2023
Aetna, Sciatica, Kyphosis, Elevance Health, DISC, Cigna, Medicare, Suite, Blue Shield, Patient, Physician, Marina del Rey, California, Flying disc sports, Sports medicine, Ventura Boulevard, Environment, Spinal stenosis, Scoliosis, Nursing, San Fernando Valley, UnitedHealth Group

NEWPORT BEACH, Calif., May 25, 2023 /PRNewswire/ -- DISC Sports & Spine Center ("DISC") continues to expand the reach of its world-class services with the announcement of a new clinic in Encino. Located at 16830 Ventura Boulevard, Suite 220, Encino, CA 91436 (map it), the modern satellite clinic will give San Fernando Valley residents convenient access to DISC's leading-edge spine care and sports medicine.

Key Points: 
  • Dr. Luke Macyszyn is now accepting new patients for leading-edge spine care at the modern, convenient Encino location.
  • NEWPORT BEACH, Calif., May 25, 2023 /PRNewswire/ -- DISC Sports & Spine Center ("DISC") continues to expand the reach of its world-class services with the announcement of a new clinic in Encino.
  • Located at 16830 Ventura Boulevard, Suite 220, Encino, CA 91436 ( map it ), the modern satellite clinic will give San Fernando Valley residents convenient access to DISC's leading-edge spine care and sports medicine.
  • Dr. Luke Macyszyn has already begun to see patients in Encino, and will continue to offer office hours in Marina del Rey as well.

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Retrieved on: 
Friday, May 19, 2023
Kaufman, UNIPD, Prefrontal cortex, Cerebrospinal fluid, Plasma, Motion, Frasier, Protein, Thalamus, Acquisition, Patient, Atidarsagene autotemcel, Randomized controlled trial, The New England Journal of Medicine, Cell, Disease, IDUA, UOM, Enzyme replacement therapy, Phenotype, DSM-IV codes, Tissue, University, Hip, Gene, Orchard, GRN, Dementia, San Raffaele Hospital, Growth, HSC, Cognition, Natural history, Kyphosis, Biomarker, MPS, Șaeș, Frontotemporal dementia, Webcast, Mortality, Therapy, Central nervous system, Doctor of Philosophy, Speech, HSCT, CNS, EDT, Health, MRI, SGSH, Dysplasia, Society, FTD, Finnish heritage disease, Hippocampus, Medical imaging, Pharmaceutical industry, Vaccine, Medical device, Nursing, Dentistry

BOSTON and LONDON, May 19, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic and neurodegenerative disorders. The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

Key Points: 
  • The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
  • At baseline, most patients presented with severe joint range of motion impairment, severe acetabular (hip) dysplasia and varying degrees of dorso-lumbar kyphosis.
  • Treatment with OTL-203 was generally well tolerated and demonstrated extensive metabolic correction over four years after treatment.
  • Data from in vivo studies indicate effective GRN protein delivery to the CNS of knockout mice transplanted with gene-modified HSCs.

Medacta showcases NextAR Spine MIS LT procedure at Spine Week, efficiently complementing operative workflow for spine surgery

Retrieved on: 
Wednesday, May 3, 2023
Spine, Surgeon, Education, Workflow, Institute of technology, Westmead Hospital, Kyphosis, Medicine, Surgery, Congress, Ecosystem, Abdominal ultrasonography, Sports medicine, Bookbinding, Medical device, Dentistry, Orthopedic surgery

Medacta showcases NextAR Spine MIS LT procedure at Spine Week, efficiently complementing operative workflow for spine surgery

Key Points: 
  • Medacta showcases NextAR Spine MIS LT procedure at Spine Week, efficiently complementing operative workflow for spine surgery
    CASTEL SAN PIETRO, May 3, 2023 - Medacta Group SA (“Medacta”, SIX:MOVE), a Swiss company specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for Joint Replacement, sports medicine, and spine surgeries, showcases its innovative NextAR Spine MIS LT procedure at Spine Week.
  • Dr. Andrew Kam, Westmead Hospital, adds, “With NextAR MIS LT, I was impressed with how the NextAR technology has been enhanced in percutaneous surgeries.
  • LT system improve the procedure's workflow and the patient's outcomes.”
    The NextAR Spine MIS LT procedure combines:
    NextAR Spine augmented reality surgical application empowers the surgeon’s vision with unique real-time surgical guidance, superimposed onto the operative field to enhance precision and enable data-driven decision-making.
  • To learn more about the NextAR Spine MIS LT procedure, visit Medacta during Spine Week at booth number B13.

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

Retrieved on: 
Friday, March 3, 2023
Achondroplasia, Mutation, Quality of life, Obstructive sleep apnea, Kyphosis, PALO, Infigratinib, Health, Cancer, Webcast, Spinal stenosis, Clinical trial, EU, FGFR3

Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.

Key Points: 
  • Infigratinib is an oral small molecule designed to inhibit fibroblast growth factor receptor 3 (FGFR3) and target achondroplasia at its source.
  • Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis.
  • To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com .
  • A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

ScoliCare Opens its First Clinic in the US

Retrieved on: 
Tuesday, November 8, 2022
Kyphosis, Growth, Rehabilitation, Scoliosis, Prevalence, Patient, CEO, Medicine

NAPLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- ScoliCare, Australia's largest provider of non-surgical scoliosis and hyperkyphosis treatment and leading worldwide brace manufacturer (ScoliBrace®), today announced the opening of its first clinic in the United States. ScoliCare Naples Florida is located at 6291 Naples Blvd, Naples, Florida. To see case studies showing how ScoliCare clinics have supported past patients, visit www.scolicare.com/naples-florida.

Key Points: 
  • ScoliCare Naples Florida is located at 6291 Naples Blvd, Naples, Florida.
  • To see case studies showing how ScoliCare clinics have supported past patients, visit www.scolicare.com/naples-florida .
  • We're really excited and proud to be the first ScoliCare clinic in the US," said Dr. T. Bryant D.C., Head Clinician of ScoliCare Naples Florida.
  • ScoliCare is known for patient-centred care and provides treatment to babies, children, adolescents and adults with scoliosis or hyperkyphosis.

Spinal Implants and Surgery Devices Global Market Report 2022: Increasing Prevalence of Spinal Disorders Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Surgery, Health, Medical Devices, Adoption, Titanium, Movement, Scoliosis, Prevalence, Biomaterial, MI, CAGR, Kyphosis, Patient, Spondylolisthesis, Back pain, Degenerative disc disease, Spine, Obesity, Deformity, COVID-19, National Center for Spinal Disorders, Growth

The "Spinal Implants and Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spinal Implants and Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global spinal implants and surgery devices market size reached US$ 10.8 Billion in 2021.
  • Spinal implants and surgery devices refer to the medical equipment used to treat spinal deformities and disorders.
  • The increasing prevalence of spinal disorders, such as degenerative disc disease, scoliosis, kyphosis and spondylolisthesis, is one of the key factors driving the growth of the market.

Zavation Medical Products, LLC, receives FDA 510K Clearance for Varisync™ Anterior Cervical Plate and Spacer system as an addition to its cervical spine portfolio

Retrieved on: 
Thursday, August 18, 2022
FDA, Multimedia, Degenerative disc disease, Fracture, Spondylolisthesis, Surgeon, MS, Neck pain, Nonunion, LLC, Trauma, Research, History, The Company, Neoplasm, Patient, Company, Kyphosis, View, Genesis Revisited II, Lordosis, Spinal stenosis, Deformity, Medicine, MIS, Scoliosis, DDD, Medical device, Dentistry, Medical imaging, Zavat

Zavation Medical Products, LLC, receives FDA 510K Clearance for Varisync Anterior Cervical Plate and Spacer system as an addition to its cervical spine portfolio.

Key Points: 
  • Zavation Medical Products, LLC, receives FDA 510K Clearance for Varisync Anterior Cervical Plate and Spacer system as an addition to its cervical spine portfolio.
  • Varisync, the most recent addition to the Zavation cervical spine portfolio, has been tested and approved for both the independent and synchronized use of its plate and spacer components.
  • This allows Zavation's surgeon partners to use these plate and spacer options together as a system or pair individual components with any of Zavation's existing cervical portfolio options.
  • These devices are intended to be used with supplemental fixation such as the Zavation VariSyncPlate, Zavation Midline Plate, Zavation EZ Plate, or Zavation Cervical Plate Systems.

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

Retrieved on: 
Tuesday, July 26, 2022
GLOBE, Sex, AHV, FGFR3, ACH, First grade, Health, Patent, Obstructive sleep apnea, SAE, AE, AES, Cancer, Nasdaq, PALO, Cohort, PROPEL, Mutation, Spinal stenosis, Growth, Kyphosis, Copper, Pharmaceutical industry, Vaccine, Achondroplasia

PALO ALTO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive interim results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. Achondroplasia (ACH) is the most common cause of disproportionate short stature. Achondroplasia impacts health and can lead to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. Achondroplasia affects approximately 55,000 people in the United States (US) and Europe, including up to 13,000 children and adolescents with open growth plates. The condition is uniformly caused by an activating mutation in fibroblast growth factor receptor 3 (FGFR3). Infigratinib is an oral small molecule that inhibits FGFR3, therefore designed to target this well-described disease at its source.

Key Points: 
  • Achondroplasia impacts health and can lead to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis.
  • Infigratinib is an oral small molecule that inhibits FGFR3, therefore designed to target this well-described disease at its source.
  • An increase in AHV over baseline of 0.22 cm/yr (p=0.54, n=38) was observed across these earlier combined cohorts for children 5 years of age and older.
  • Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.

Spine Implants Global Market Report 2022: A $15.77 Billion Market in 2026 - Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 10, 2022
Surgery, Health, Titan, Woman, National Center for Biotechnology Information, MIS, National Center for Spinal Disorders, Disorder, Adult, Scoliosis, Spinal stenosis, Vertebral compression fracture, Man, Johnson & Johnson, Spine, RTI, RTI Surgical, Medtronic, VCF, LSS, Degenerative disc disease, Female, Solution, Globus Medical, Fracture, MISS, FDA, Growth, Stryker Corporation, Male, Patient, Hospital, Employment, Technology, Spondylolisthesis, Anatomy, Acquisition, NuVasive, Prevalence, Population, Titanium, Muscle, Kyphosis, Spinal fusion, Lumbar spinal stenosis, Deformity, Stainless steel, Medical device, Pharmaceutical industry, Bookbinding, Ceramic, Dentistry, Health insurance

The market consists of revenue generated by the companies manufacturing spine implants by the sales of these products.

Key Points: 
  • The market consists of revenue generated by the companies manufacturing spine implants by the sales of these products.
  • The main products in the spine implants are spinal fusion devices, non-fusion devices/motion preservation devices, vertebral compression fracture (VCF) treatment devices, spinal bone stimulators, spine biologics.
  • The innovation of implants in providing minimally invasive and motion-preserving stabilization is a major trend in the spine implants market.
  • Global Spine Implants Forecast Market, 2021-2026F, 2031F, $ Billion